UA63888C2 - Nucleotide sequence, able to inhibit activity of il-6, use thereof for therapy, plasmide vector and pharmaceutical composition (alternatives) containing this nucleotide sequence - Google Patents

Nucleotide sequence, able to inhibit activity of il-6, use thereof for therapy, plasmide vector and pharmaceutical composition (alternatives) containing this nucleotide sequence Download PDF

Info

Publication number: UA63888C2
Authority: UA; Ukraine
Prior art keywords: nucleotide sequence; plasmid; sequence; inhibitory; cells
Prior art date: 1995-05-11

Application number

UA97126018A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-11

Filing date

1995-11-05

Publication date

2004-02-16

1995-11-05 Application filed by Applied Research Systems filed Critical Applied Research Systems

2004-02-16 Publication of UA63888C2 publication Critical patent/UA63888C2/uk

Links

239000002773 nucleotide Substances 0.000 title claims abstract description 40
125000003729 nucleotide group Chemical group 0.000 title claims abstract description 39
230000000694 effects Effects 0.000 title claims abstract description 27
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
238000002560 therapeutic procedure Methods 0.000 title claims abstract description 4
239000013598 vector Substances 0.000 title description 4
108091023040 Transcription factor Proteins 0.000 claims abstract description 15
102000040945 Transcription factor Human genes 0.000 claims abstract description 15
230000027455 binding Effects 0.000 claims abstract description 14
108700039691 Genetic Promoter Regions Proteins 0.000 claims abstract description 7
230000002401 inhibitory effect Effects 0.000 claims description 63
238000001890 transfection Methods 0.000 claims description 29
108091034117 Oligonucleotide Proteins 0.000 claims description 8
230000009471 action Effects 0.000 claims description 4
239000013600 plasmid vector Substances 0.000 claims description 4
230000001105 regulatory effect Effects 0.000 claims description 3
206010048998 Acute phase reaction Diseases 0.000 claims description 2
210000004962 mammalian cell Anatomy 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
102000004889 Interleukin-6 Human genes 0.000 abstract 1
108090001005 Interleukin-6 Proteins 0.000 abstract 1
239000013612 plasmid Substances 0.000 description 143
210000004027 cell Anatomy 0.000 description 61
108700008625 Reporter Genes Proteins 0.000 description 41
108020004414 DNA Proteins 0.000 description 38
108060001084 Luciferase Proteins 0.000 description 32
239000012634 fragment Substances 0.000 description 25
239000005089 Luciferase Substances 0.000 description 21
238000002474 experimental method Methods 0.000 description 21
238000004458 analytical method Methods 0.000 description 19
230000005764 inhibitory process Effects 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 19
108091028043 Nucleic acid sequence Proteins 0.000 description 14
230000006698 induction Effects 0.000 description 10
238000001962 electrophoresis Methods 0.000 description 7
238000011282 treatment Methods 0.000 description 7
239000011543 agarose gel Substances 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
150000007523 nucleic acids Chemical class 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
241000700605 Viruses Species 0.000 description 5
238000013459 approach Methods 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
206010073071 hepatocellular carcinoma Diseases 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
238000012360 testing method Methods 0.000 description 5
206010006187 Breast cancer Diseases 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
241000233803 Nypa Species 0.000 description 4
235000005305 Nypa fruticans Nutrition 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000010276 construction Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
241000283690 Bos taurus Species 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108050005077 Haptoglobin Proteins 0.000 description 3
101001078385 Homo sapiens Haptoglobin Proteins 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000006713 insertion reaction Methods 0.000 description 3
208000025113 myeloid leukemia Diseases 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
108091035707 Consensus sequence Proteins 0.000 description 2
102000006580 General Transcription Factors Human genes 0.000 description 2
108010008945 General Transcription Factors Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000014702 Haptoglobin Human genes 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000004891 communication Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000003571 reporter gene assay Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000005070 sampling Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
HRGUSFBJBOKSML-UHFFFAOYSA-N 3',5'-di-O-methyltricetin Chemical compound COC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 HRGUSFBJBOKSML-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108010074051 C-Reactive Protein Proteins 0.000 description 1
102100032752 C-reactive protein Human genes 0.000 description 1
208000005024 Castleman disease Diseases 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
101100369915 Drosophila melanogaster stas gene Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
235000006538 Opuntia tuna Nutrition 0.000 description 1
244000237189 Opuntia tuna Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
IDDMFNIRSJVBHE-UHFFFAOYSA-N Piscigenin Natural products COC1=C(O)C(OC)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 IDDMFNIRSJVBHE-UHFFFAOYSA-N 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
239000005516 coenzyme A Substances 0.000 description 1
229940093530 coenzyme a Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000011536 extraction buffer Substances 0.000 description 1
230000001723 fibrinogenic effect Effects 0.000 description 1
230000009454 functional inhibition Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
210000005096 hematological system Anatomy 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
102000050796 human HP Human genes 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
BMCJATLPEJCACU-UHFFFAOYSA-N tricin Natural products COc1cc(OC)c(O)c(c1)C2=CC(=O)c3c(O)cc(O)cc3O2 BMCJATLPEJCACU-UHFFFAOYSA-N 0.000 description 1
JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
210000002268 wool Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA97126018A 1995-05-11 1995-11-05 Nucleotide sequence, able to inhibit activity of il-6, use thereof for therapy, plasmide vector and pharmaceutical composition (alternatives) containing this nucleotide sequence UA63888C2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP1995/001778 WO1996035782A1 (fr)	1995-05-11	1995-05-11	Inhibiteur de l'activite de il-6

Publications (1)

Publication Number	Publication Date
UA63888C2 true UA63888C2 (en)	2004-02-16

Family

ID=8166014

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA97126018A UA63888C2 (en)	1995-05-11	1995-11-05	Nucleotide sequence, able to inhibit activity of il-6, use thereof for therapy, plasmide vector and pharmaceutical composition (alternatives) containing this nucleotide sequence

Country Status (16)

Country	Link
US (1)	US6004813A (fr)
EP (1)	EP0824588B1 (fr)
JP (1)	JP4173539B2 (fr)
KR (1)	KR100449677B1 (fr)
AT (1)	ATE271128T1 (fr)
AU (1)	AU715125B2 (fr)
CA (1)	CA2220433C (fr)
DE (1)	DE69533264T2 (fr)
DK (1)	DK0824588T3 (fr)
ES (1)	ES2220929T3 (fr)
IL (1)	IL118158A (fr)
MX (1)	MX9708663A (fr)
RU (1)	RU2205874C2 (fr)
UA (1)	UA63888C2 (fr)
WO (1)	WO1996035782A1 (fr)
ZA (1)	ZA963593B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6727230B1 (en)	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
CA2237114A1 (fr) *	1995-11-07	1997-05-15	Kaneka Corporation	Autoantigenes
EP0855184A1 (fr) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination
WO1998037919A1 (fr)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	UTILISATION D'ACIDES NUCLEIQUES CONTENANT DES DINUCLEOTIDES CpG NON METHYLES DANS LE TRAITEMENT DES TROUBLES ASSOCIES AUX LIPOPOLYSACCHARIDES
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (fr)	1997-05-20	2007-08-22	Ottawa Health Research Institute	Procedes de preparation de constructions d'acides nucleiques
AU760549B2 (en)	1998-04-03	2003-05-15	University Of Iowa Research Foundation, The	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP0972780A1 (fr) *	1998-05-18	2000-01-19	Applied Research Systems ARS Holding N.V.	Peptides antagonistes de l'Il-6
BR9913562A (pt)	1998-09-11	2001-05-22	Ajinomoto Kk	Derivados de benzeno, inibidor de ativação de ap-1 e nf-capa b, inibidor de produção de citoquina inflamatória, inibidor de produção de metaloprotease matricial ou inibidor de aparecimento de fator de adesão de célula inflamatório, e, agente antiinflamatório, anti-reumático, imunossupressor, inibidor de metástase cancerosa, remédio para arterioesclerose e agente antiviral
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
AU7078200A (en)	1999-08-27	2001-03-26	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
AU2001227889A1 (en)	2000-01-14	2001-07-24	The United States of America, represented by The Secretary, Department of Health & Human Services	Oligodeoxynucleotide and its use to induce an immune response
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
EP1296714B1 (fr)	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Combinaison de CpG et d'anticorps contre le CD19, CD20, CD22 ou CD40 pour la prévention ou pour le traitement du cancer.
WO2003020884A2 (fr)	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Procede de generation rapide de cellules dentritique matures
WO2003054161A2 (fr)	2001-12-20	2003-07-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Utilisation d'oligodeoxynucleotides cpg en vue d'induire l'angiogenese
AU2003216585A1 (en) *	2002-04-10	2003-10-20	Orchid Chemicals And Pharmaceuticals Limited	Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
US6794401B2 (en) *	2003-01-17	2004-09-21	Bexel Pharmaceuticals, Inc.	Amino acid phenoxy ethers
US7521465B2 (en) *	2003-01-17	2009-04-21	Bexel Pharmaceuticals, Inc.	Diphenyl ether derivatives
US7781464B2 (en) *	2003-01-17	2010-08-24	Bexel Pharmaceuticals, Inc.	Heterocyclic diphenyl ethers
US7087576B2 (en) *	2003-10-07	2006-08-08	Bexel Pharmaceuticals, Inc.	Dipeptide phenyl ethers
AU2005235811B2 (en) *	2004-02-06	2011-11-03	Morphosys Ag	Anti-CD38 human antibodies and uses therefor
EP1858845A2 (fr) *	2005-03-18	2007-11-28	Orchid Chemicals and Pharmaceuticals Limited	Nouveaux derives de tyrosine
US20080267888A1 (en) *	2005-05-26	2008-10-30	Pandey Surendrakumar Satyanara	Heterocyclic Derivatives
JP2008543968A (ja) *	2005-06-28	2008-12-04	オーキッドリサーチラボラトリーズリミテッド	新規なピラゾロピリミジノン誘導体
CA2625681C (fr)	2005-10-12	2016-08-02	Morphosys Ag	Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain
PL1973884T3 (pl) *	2006-01-19	2017-05-31	Orchid Pharma Limited	Nowe związki heterocykliczne
US7863446B2 (en) *	2006-01-19	2011-01-04	Orchid Research Laboratories Limited	Heterocycles
WO2008110891A2 (fr) *	2007-03-09	2008-09-18	Orchid Research Laboratories Limited,	Nouveaux dérivés hétérocycliques
US7943591B2 (en) *	2007-05-11	2011-05-17	Adynxx, Inc.	Gene expression and pain
BRPI0912029A2 (pt)	2008-02-01	2020-06-30	Orchid Research Laboratories Limited	novos heterociclos
CN102282155B (zh)	2008-12-02	2017-06-09	日本波涛生命科学公司	磷原子修饰的核酸的合成方法
RU2612521C2 (ru)	2009-07-06	2017-03-09	Онтории, Инк.	Новые пролекарства нуклеиновых кислот и способы их применения
JP5868324B2 (ja)	2010-09-24	2016-02-24	株式会社Wave Life Sciences Japan	不斉補助基
CN103796657B (zh)	2011-07-19	2017-07-11	波涛生命科学有限公司	合成官能化核酸的方法
PT2846839T (pt)	2012-05-10	2019-05-29	Adynxx Inc	Formulações para a administração de ingredientes ativos
CA2879066C (fr)	2012-07-13	2019-08-13	Shin Nippon Biomedical Laboratories, Ltd.	Adjuvant d'acide nucleique chiral
PL2872485T3 (pl)	2012-07-13	2021-05-31	Wave Life Sciences Ltd.	Asymetryczna grupa pomocnicza
KR102213609B1 (ko)	2012-07-13	2021-02-08	웨이브 라이프 사이언시스 리미티드	키랄 제어
JPWO2015108048A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en)	2014-01-15	2019-06-18	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108047A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
BR112016016400A2 (pt)	2014-01-16	2017-10-03	Wave Life Sciences Ltd	Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
RU2017108238A (ru)	2014-08-15	2018-09-17	Эйдинкс, Инк.	Олигонуклеотиды-приманки для лечения боли

1995
- 1995-05-11 AT AT95919438T patent/ATE271128T1/de active
- 1995-05-11 MX MX9708663A patent/MX9708663A/es unknown
- 1995-05-11 US US08/945,726 patent/US6004813A/en not_active Expired - Lifetime
- 1995-05-11 KR KR1019970708022A patent/KR100449677B1/ko not_active Expired - Lifetime
- 1995-05-11 ES ES95919438T patent/ES2220929T3/es not_active Expired - Lifetime
- 1995-05-11 WO PCT/EP1995/001778 patent/WO1996035782A1/fr not_active Ceased
- 1995-05-11 JP JP53368396A patent/JP4173539B2/ja not_active Expired - Lifetime
- 1995-05-11 AU AU25267/95A patent/AU715125B2/en not_active Expired
- 1995-05-11 CA CA2220433A patent/CA2220433C/fr not_active Expired - Lifetime
- 1995-05-11 DE DE69533264T patent/DE69533264T2/de not_active Expired - Lifetime
- 1995-05-11 DK DK95919438T patent/DK0824588T3/da active
- 1995-05-11 EP EP95919438A patent/EP0824588B1/fr not_active Expired - Lifetime
- 1995-05-11 RU RU97120584/13A patent/RU2205874C2/ru active
- 1995-11-05 UA UA97126018A patent/UA63888C2/uk unknown
1996
- 1996-05-06 IL IL11815896A patent/IL118158A/en not_active IP Right Cessation
- 1996-05-07 ZA ZA963593A patent/ZA963593B/xx unknown

Also Published As

Publication number	Publication date
ZA963593B (en)	1996-11-25
DE69533264T2 (de)	2004-11-25
US6004813A (en)	1999-12-21
CA2220433C (fr)	2010-02-16
DE69533264D1 (de)	2004-08-19
JPH11504816A (ja)	1999-05-11
EP0824588A1 (fr)	1998-02-25
AU2526795A (en)	1996-11-29
ES2220929T3 (es)	2004-12-16
ATE271128T1 (de)	2004-07-15
IL118158A (en)	2004-07-25
WO1996035782A1 (fr)	1996-11-14
EP0824588B1 (fr)	2004-07-14
CA2220433A1 (fr)	1996-11-14
JP4173539B2 (ja)	2008-10-29
DK0824588T3 (da)	2004-08-16
MX9708663A (es)	1998-02-28
KR100449677B1 (ko)	2004-11-20
RU2205874C2 (ru)	2003-06-10
KR19990014681A (ko)	1999-02-25
AU715125B2 (en)	2000-01-20
IL118158A0 (en)	1996-09-12
HK1016213A1 (en)	1999-10-29

Publication	Publication Date	Title
UA63888C2 (en)	2004-02-16	Nucleotide sequence, able to inhibit activity of il-6, use thereof for therapy, plasmide vector and pharmaceutical composition (alternatives) containing this nucleotide sequence
Goldberg et al.	1988	Activation of protein kinase C or cAMP‐dependent protein kinase increases phosphorylation of the c‐erbA‐encoded thyroid hormone receptor and of the v‐erbA‐encoded protein.
Kappler et al.	1993	Insect immunity. Two 17 bp repeats nesting a kappa B‐related sequence confer inducibility to the diptericin gene and bind a polypeptide in bacteria‐challenged Drosophila.
MXPA97008663A (en)	1998-02-01	Activity inhibitor i
KR0148782B1 (ko)	1998-08-17	유전자 발현에 영향을 주는 다수의 표적반응요소를 가진 벡터
JP2011225571A (ja)	2011-11-10	Ｍｄｍ２タンパク質の腫瘍原活性のアンタゴニスト及び癌治療におけるその使用
JP2001299373A (ja)	2001-10-30	ｅｒｂＢ−３ポリペプチドをコードするＤＮＡセグメント、前記ポリペプチドを検出するための抗体及びバイオアッセイ
Cameron et al.	1991	Inhibition of gene expression by a short sense fragment
Hillman et al.	2001	Fragile XE-associated familial mental retardation protein 2 (FMR2) acts as a potent transcription activator
JPH09510346A (ja)	1997-10-21	哺乳動物細胞における新生物形質転換の制御に関連する遺伝子および遺伝学的因子
Falzon et al.	1988	Multiple protein-binding sites in an intracisternal A particle long terminal repeat
KR102092981B1 (ko)	2020-03-24	조절된 유전자 발현 방법
Nakamura et al.	2002	Cytokine receptor common β subunit-mediated STAT5 activation confers NF-κB activation in murine proB cell line Ba/F3 cells
Piatak et al.	1983	Sequences locating the 5'ends of the major simian virus 40 late mRNA forms
Mehra-Chaudhary et al.	2001	Msx3 protein recruits histone deacetylase to down-regulate the Msx1 promoter
US5981188A (en)	1999-11-09	Method for identifying agents that modulate transcription of human cytomegalovirus polymerase
US20030083482A1 (en)	2003-05-01	Compositions and methods for p53-mediated repression of gene expression
Jacquemin-Sablon et al.	1992	Organization of the unrl N-ras locus: characterization of the promoter region of the human unr gene
Shore et al.	1994	Structural alterations in the carboxyl-terminal domain of the BCRABL gene product activate its fibroblastic transforming potential.
Nakshatri et al.	1991	Activity and enhancer binding factors for BK virus regulatory elements in differentiating embryonal carcinoma cells
US20060257367A1 (en)	2006-11-16	Tumour-cell specific gene expression and its use in cancer therapy
Son et al.	2002	ATF is important to late S phase-dependent regulation of DNA topoisomerase IIα gene expression in HeLa cells
CA2227306A1 (fr)	1997-03-27	Manipulation et detection de la proteine phosphatase 2c-pp2c.alpha.- expression dans des cellules cancereuses pour la prevention, la detection et la therapie du cancer
Canalis et al.	0	https://www. jbc. org/cgi/doi/10.1074/jbc. RA119. 011440 The latest version is at
DiPietro et al.	2006	332. Routes of Ligand Administration That Give Efficient and Robust In Vivo Induction with the RheoSwitch® Therapeutic System